Gateways to clinical trials

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 28, Issue 5, 2006, Pages 323-343

  Bayes M ^a   Rabasseda, X ^b   Prous, J R ^b  

^a PROUS SCIENCE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2BETA (3 HYDROXYPROPOXY)CALCITRIOL; ADALIMUMAB; ALBUMIN ALPHA INTERFERON; ALEMTUZUMAB; ALISKIREN; AMINOLEVULINIC ACID METHYL ESTER; ATOMOXETINE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; BEVACIZUMAB; BOSENTAN; BRIMONIDINE; CANGRELOR; CETUXIMAB; CICLESONIDE; CINACALCET; DARUSENTAN; DESLORATADINE; DULOXETINE; EFALIZUMAB; ELCATONIN; ENTECAVIR; ETORICOXIB; FENRETINIDE; FLUDARABINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXYBATE SODIUM; RAZOXANE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TIMOLOL MALEATE; UNINDEXED DRUG;

ACTINIC KERATOSIS; ACUTE PANCREATITIS; ALLERGIC RHINITIS; ALLERGY; ANALGESIA; ANEMIA; ANKYLOSING SPONDYLITIS; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ATTENTION DEFICIT DISORDER; BLEEDING; BLOOD DISEASE; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DEPRESSION; DRUG RESEARCH; GLAUCOMA; HEPATITIS B; HEPATITIS C; HUMAN; HYPERCALCEMIA; HYPERTENSION; IMMUNOPATHOLOGY; LEUKEMIA; LUNG CANCER; LYMPHATIC SYSTEM DISEASE; OSTEOPOROSIS; PANCREAS CANCER; PANNICULITIS; POSTOPERATIVE PAIN; PSORIASIS; REVIEW; VENOUS THROMBOEMBOLISM;

CLINICAL TRIALS; HUMANS;

EID: 33745925602     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Hedenus, M. et al. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: Disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 2005, 23(28): 6941.
2. Conde, S., Figueiredo, A., Barroso, A., Teixeira, E., Parente, B., Barata, F. Darbepoetin alfa dosed every 3 weeks in chemotherapy-induced anemia in patients with lung cancer. Lung Cancer 2005, 49(Suppl 2): Abst P-806.
3. Storey, R.F. et al. AZD6140 yields greater inhibition of platelet aggregation than clopidogrel in patients with acute coronary syndromes without previous clopidogrel treatment. J Am Coll Cardiol 2006, 47(4, Suppl 1): Abst 821-3.
4. Storey, R.F. et al. AZD6140 yields additional suppression of platelet aggregation in patients with acute coronary syndromes previously treated with clopidogrel. J Am Coll Cardiol 2006, 47(4, Suppl 1): Abst 821-4.
5. Husted, S. et al. The effects of AZD6140, the first oral reversible adenosine diphosphate receptor antagonist, compared with clopidogrel on biochemical markers in patients with acute coronary syndromes. J Am Coll Cardiol 2006, 47(4, Suppl 1): Abst 974-245.
6. Lee, C.W., Park, D.W., Lee, B.K. et al. Predictors of restenosis after placement of drug-eluting stents in one or more coronary arteries. Am J Cardiol 2006, 97(4): 506.
7. Greenbaum, A.B., Grines, C.L., Bittl, J.A. et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 2006, 151(3): 689.e1.
8. Chu, W.W., Rha, S.W., Kuchulakanti, P.K. et al. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006, 97(1): 34.
9. Cohen, A.T., Davidson, B.L., Gallus, A.S. et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomised placebo controlled trial. Br Med J 2006, 332(7537): 325.
10. Leyva, F., Gibbs, C.R., Jordan, P., Smith, R.E., Muhyaldeen, S., Chalil, S.B. Delayed gadolinium enhancement magnetic resonance imaging is superior to QRS duration and echocardiographic measures of cardiac dyssynchrony in predicting benefit from cardiac resynchronization therapy. Circulation 2005, 112(17, Suppl 2): Abst 3372.
11. Smith, C.S. et al. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: Observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. Am Heart J 2005, 149(3): 444.
12. Koren, M.J. et al. Ranolazine safety and tolerability during long-term treatment of stable angina. J Am Coll Cardiol 2006, 47(4, Suppl 1): Abst 999-253.
13. Nissen, S.E. et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006, 295: 1556-65.
14. Trevi, G., Meliga, E., Sciuto, F. et al. Treatment of recurrent and diffuse instent restenosis with sirolimus-eluting stent: Long-term outcome. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-299.
15. Roy, L., Plante, S., Mildenberger, R.R. et al. Efficacy and safety at 3 years of the sirolimus-eluting stent for the treatment of patients with long lesions in small vessels from the Canadian multicenter, randomized, double-blind trial C-SIRIUS. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-109.
16. Park, Y.-B., Oh, B.H., Kim, H.-S. et al. Outcomes of sirolimus- and paclitaxel-eluting stents in unselected patients: SNUH-DES registry experience. Am J Cardiol 2005, 95(8A, Suppl): Abst AS-102.
17. Hoeper, M.M. et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005, 26(5): 858.
18. Seyfarth, H.J., Pankau, H., Hammerschmidt, S., Schauer, J., Wirtz, H., Winkler, J. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. Chest 2005, 128(2): 709.
19. Black, H. et al. Darusentan antihypertensive effect in patients with resistant hypertension. J Am Coll Cardiol 2006, 47(4, Suppl 1): Abst 915-208.
20. Nussberger, J., Jensen, C., Stanton, A., O'Brien, E. Aliskiren, an orally effective renin inhibitor, suppresses plasma renin activity and improves blood pressure lowering in combination with irbesartan in patients with hypertension. Circulation 2005, 112(17, Suppl 2): Abst 2224.
21. Shimano, K., Takashiba, M., Kajimoto, Y., Nakagawa, S., Kajimoto, O. Evaluation of the safety in excess administration of tea beverage containing peptide derived from sardine muscle hydrolyzate on humans. Jpn Pharmacol Ther 2005, 33(11): 1113.
22. Craven, E.R. et al. Brimonidine and timolol fixed-combination therapy versus monotherapy: A 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocular Pharmacol Ther 2005, 21(4): 337.
23. Pioda, G., Nicasi, A., Cristallini, S., Filipponi, P. Cinacalcet in a case of hypocalciuric hypercalcemia with recurrent pancreatitis. J Bone Miner Res 2005, 20 (Suppl 1): Abst SU509.
24. Lacy, B.E. et al. Tegaserod reduces multiple symptoms across overlapping GI disorders: Results from a self-reported patient questionnaire. Am J Gastroenterol 2005, 100(9, Suppl): Abst 935.
25. Varshney, S. et al. Effect of tegaserod on colonic motility. Am J Gastroenterol 2005, 100(9, Suppl): Abst 915.
26. Sulkowski, M.S., Nelson, D.R., Balan, V. et al. A phase I/II study evaluating escalating doses of recombinanl human albumin-interferon-α fusion protein in chronic hepatitis C patients who have failed previous interferon-α-hased therapy. Antivir Ther 2006, 11(1): 35.
27. Malik, A.H., Nelson, S.D., Lindsey, J.L., Angtuaco, T.L., Moore, C.H. No difference in efficacy and tolerability between pegylated Interferon alfa-2a vs. alfa-2b in combination with ribavirin in treatment of naive patients with chronic hepatitis C. Am J Gastroenterol 2005, 100(9, Suppl): Abst 262.
28. Ratner, P.H. et al. Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 653.
29. Pauli, G., Becker, J., Purohit, A., Frossard, N. Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine: A double-blind placebo-controlled study. J Eur Acad Dermatol Venereol 2005, 19 (Suppl 2): Abst P03.87.
30. Lok, A.S., Shouval, D., Lai, C.-L. et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354(10): 1011.
31. de Man, R., Gish, R.G., Chang, T.-T. et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354(10): 1001.
32. Ockenhouse, C.F., Angov, E., Kester, K.E. et al. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine 2006, 24(15): 3009.
33. Cerulli, M.A., Posner, G., Elsiesy, H., Mansour, M., Iqbal, S. 24 Weeks of treatment for hepatitis C genotype 4 may be sufficient. Am J Gastroenterol 2005, 100(9, Suppl): Abst 245.
34. Dunachie, S.J., Walther, M., Vuola, J.M. et al. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine 2006, 24(15): 2850.
35. Stephan, C., Berger, A., Carlebach, A. et al. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J Antimicrob Chemother 2005, 56(6): 1087.
36. Riera, M., Barrios, A., Domingo, P. et al. Rate of virological failure and resistance mutations in anti-retroviral-experienced patients shift to a QD simplification regimen with didanosine, tenofovir and efavirenz (EFADITE trial). Antivir Ther 2005, 10(4, Suppl): S23.
37. Tesauro, M. et al. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 2005, 112(19): 2986.
38. Nissen, S.E. et al. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005, 294(20): 2581.
39. Ferdinand, K.C., Clark, L.T., Watson, K.E. et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol 2006, 97(2): 229.
40. Aggrawal, R., Khan, A., Mittal, S. Rosuvastatin induced hepatitis. Nephrology 2005, 10(Suppl): Abst M-PO50030.
41. ter Avest, E. et al. Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. Eur J Clin Invest 2005, 35(9): 558.
42. Wong, R., Rahman, P., Inman, R.D., Patra, K., Maksymowych, W.P. Adalimumab suppresses biomarkers of cartilage degradation in active ankylosing spondylitis - results of the Canadian AS study. Arthritis Rheum 2005, 52(9, Suppl): Abst L6.
43. Hufford, M.J., Wolfe, F., Pangan, A.L., Kent, J.D. Diurnal variation of pain, fatigue, function and disease activity in patients with active rheumatoid arthritis: Preliminary results from the HUMIRA Efficacy Response Optimization (HERO) study. Arthritis Rheum 2005, 52(9, Suppl): Abst 1066.
44. Pascual, V., Stichweh, D., Allantaz, F., Punaro, L. Clinical and microarray follow-up of systemic onset juvenile idiopathic arthritis patients treated with anakinra. Clin Exp Rheumatol 2005, 23(3, Suppl 37): Abst O-242.
45. Alcocer-Varela, J., Sr., Teliz-Meneses, M.A., Sr., Romero-Trejo, C., Furuzawa-Carballeda, J. Intramuscular administration of polymerized type I collagen for the treatment of patients with rheumatoid arthritis: A double blind placebo-controlled clinical trial. Arthritis Rheum 2005, 52(9, Suppl): Abst 1500.
46. Hagino, H., Miki, T., Matsumoto, T. et al. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: A randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2005, 90(9): 5031.
47. Furst, D., Reed, G., Kremer, J. et al. Rheumatoid arthritis patients on TNF blockers have higher rates of infection. Arthritis Rheum 2005, 52(9, Suppl): Abst 1453.
48. Krege, J.H., Glass, E.V., Crans, G.G., Prevrhal, S., Genant, H. Teriparatide reduces vertebral height loss in women with osteoporosis: Results from the fracture prevention trial. Arthritis Rheum 2005, 52(9, Suppl): Abst 723.
49. Thiebaud, D., Ta, F., Wilawan, K. et al. A comparison of teriparatide and calcitonin therapy in post-menopausal women with osteoporosis. Bone 2005, 36(Suppl 2): Abst P679-Su.
50. Martini, G. et al. The effect of teriparatide on bone remodeling is not related to serum levels of osteoprotegerin and RANKL. J Bone Miner Res 2005, 20(Suppl 1): Abst M416.
51. McCullough, A., Ferguson, R., Ghanta, R. et al. Use of tegaserod along with polyethylene glycol electrolyte solution for colonoscopy bowel preparation: A prospective, randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2005, 100(9, Suppl): Abst 982.
52. Fiveash, J., Shen, S., Hockaday, D.C. et al. Imaging glioma extent with 131I-TM-601. J Nucl Med 2005, 46(4): 580.
53. Shiratori, T., Matsubara, H., Shimada, H. et al. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci 2006, Epub ahead of print.
54. Meurer, M., Hesse, E., Aschoff, R. An evaluation of pain with cold air stream in actinic keratoses patients treated with MALPDT. J Eur Acad Dermatol Venereol 2005, 19(Suppl 2): Abst P08.75.
55. Kindler, H.L., Friberg, G., Singh, D.A. et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005, 23(31): 8033.
56. Hurwitz, H.I., Holden, S.N., Sarkar, S., Mass, R. Clinical benefit of hevacizumab in responding and non-responding patients with metastatic colorectal cancer. Eur J Cancer - Suppl 2005, 3(2): Abst 643.
57. Koehne, C., Pollert, P., Nolting, A. et al. Cetuximab and irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (AIO) is active and safe in the first-line treatment of metastatic colorectal cancer (mCRC) expressing the epidermal growth factor receptor (EGFR). Eur J Cancer - Suppl 2005, 3(2): Abst 702.
58. De Gramont, A., Gascon, N., Zubel, A. et al. Cetuximab plus oxaliplatin/5-fluorouracil (S-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) in the first-line setting: A phase II study. Eur J Cancer - Suppl 2005, 3(2): Abst 642.
59. Giles, F. et al. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cylarabine in patients with refractory leukemia. Clin Cancer Res 2005, 11(21): 7817.
60. Talpaz, M., Chen, T.-T., Bleickardt, E. et al. Dasatinib (BMS-354825) in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph + ALL) who are resistant or intolerant to imatinib: Update of a phase I study. Blood 2005, 106(11): Abst 38.
61. Sawyers, C., Baccarani, M., Hochhaus, A. et al. Efficacy of dasatinib in patients with chronic phase Philadelphia chromosome-positive CML resistant or intolerant to imatinib: First results of the CA180013 'START-C' phase II study. Blood 2005, 106(11): Abst 41.
62. Shah, N., Apanovitch, A., Aloe, A. et al. A phase II study of dasatinib in patients with chronic myeloid leukemia (CML) in lymphoid blast crisis or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph + ALL) who are resistant or intolerant to imatinib: The 'START-L' CA180015 study. Blood 2005, 106(11): Abst 42.
63. Sawyers, C., Coutre, S., Rosti, G. et al. A phase II study of dasatinib in patients with chronic myeloid leukemia (CML) in myeloid blast crisis who are resistant or intolerant to imatinib: First results of the CA180006 "START-B" study. Blood 2005, 106(11): Abst 40.
64. Cortes, J., Iyer, M., Chen, S. et al. A phase II study of dasatinib in patients with accelerated phase chronic myeloid leukemia (CML) who are resistant or intolerant to imatinib: First results of the CA180005 'START-A' study. Blood 2005, 106(11): Abst 39.
65. Body, J.J., Facon, T., Coleman, R.E. et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006, 12(4): 1221.
66. Morse, M.A., Garst, J., Osada, T. et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med (Online) 2005, 3(1)
67. McNeel, D.G. et al. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res 2005, 11(21): 7851.
68. Chouaid, C., Paillotin, D., Letreut, J. et al. A randomized phase II trial of docetaxel alone and in combination with gefitinib (Iressa) as second-line therapy for patients with non-small-cell lung cancer. Lung Cancer 2005, 49(Suppl 2): Abst O-091.
69. D'Adamo, D.R. et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005, 23(28): 7135.
70. Elter, T. et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: Results of a phase II trial. J Clin Oncol 2005, 23(28): 2074.
71. Wirth, L.J. et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic sauamous cell carcinoma of the head and neck. J Clin Oncol 2005, 23(28): 6976.
72. Gatzemeier, U., Reck, M. EGFR tyrosine kinase inhibitors in non-small cell lung cancer: Report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatients. Onkologie 2005, 28(12): 623.
73. Antonia, S., Simon, G., Haura, E. et al. Neoadjuvant gemcitabine and pemetrexed (NeoGP) in resectable non-small-cell lung cancer (NSCLC). Lung Cancer2005, 49(Suppl 2): Abst O-111.
74. Macfarlane, A.W., Konstantopolou, M., Belgi, A.S. Imatinib (Glivec) induced pseudoporphyria in a patient with chronic myeloid leukaemia. J Eur Acad Dermatol Venereol 2005, 19(Suppl 2): Abst P10.60.
75. Seiden, M.V., Gordon, A.N., Bodurka, D.C. et al. A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecol Oncol 2006, 101(1): 55.
76. Culver, K.W., Dugan, M., Kwong, C. et al. Oral LBH589, a novel histone deacetylase inhibitor, treatment of patients with cutaneous T-cell lymphoma (CTCL). Changes in skin gene expression profiles related to clinical response following therapy. Proc Am Assoc Cancer Res 2006, 47: Abst 1146.
77. Dritschilo, A., Huang, C.H., Rudin, CM. et al. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin Cancer Res 2006, 12(4): 1251.
78. Cohen, R.B., Rowinsky, E.K., Meropol, N.J. et al. A phase I, pharmacokinetic (PK) study of HGS-ETR1, an agonist monoclonal antibody to TRAIL-R1, in patients with advanced solid tumors. Proc Am Assoc Cancer Res 2005, 46: Abst 544.
79. Seeber, S., Galle, P.R., Bieber, F. et al. Results of a phase 2 study of HGS-ETR1, a fully human agonistic monoclonal antibody to TRAIL receptor 1, in subjects with relapsed or refractory colorectal cancer (CRC). Eur J Cancer - Suppl 2005, 3(2): Abst 630.
80. Atta, J., Arnold, R., Goekbuget, N. et al. Compound GW506U78 has high single-drug activity and good feasibility in heavily pretreated relapsed T-lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) and offers the option for cure with stem cell transplantation (SCT). Blood 2005, 106(11): Abst 150.
81. Fayad, L.E., Samaniego, F., Cabanillas, F.F. et al. Results of a phase II study of 506U78(Nelarabine) in refractory indolent B-cell or peripheral T-cell lymphoma. Blood 2005, 106(11): Abst 2681.
82. Devidas, M., Blaney, S.M., Berg, S.L. et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: A report from the Children's Oncology Group. J Clin Oncol 2005, 23(15): 3376.
83. Keating, M.J., Ernst, T.J., Kurtzberg, J. et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 2005, 23(15): 3396.
84. Quinn, J.A. et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2005, 23(28): 7178.
85. Fernando, N., Truax, R., Mahon, M. et al. Capecitabine and oxaliplatin (XELOX) in combination with bevacizumab in the treatment of metastatic colorectal cancer: Results of a phase II trial. Eur J Cancer - Suppl 2005, 3(2): Abst 667.
86. Gradishar, W.J. et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23(31): 7794.
87. Hecht, R., Jerian, S., MacDonald, M. et al. First line therapy of panitumumab, a fully human antibody, in combination with FOLFIRI for the treatment (txt) of metastatic colorectal cancer (mCRC). Eur J Cancer - Suppl 2005, 3(2): Abst 653.
88. Lara, P.N., Jr., Stadler, W.M., Longmate, J. et al. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res 2006, 12(5): 1556.
89. van Duijnhoven, F.H. et al. Photodynamic therapy with 5,10,15,20-tetrakis(m-hydroxyphenyl) bacteriochlorin for colorectal liver metastases is safe and feasible: Results from a phase I study. Ann Surg Oncol 2005, 12(10): 808.
90. Guerrieri-Gonzaga, A., Robertson, C., Bonanni, B. et al. Preliminary results on safety and activity of a randomized, double-blind, 2 × 2 trial of low-dose tamoxifen and fenretirtide for breast cancer prevention in premenopausal women. J Clin Oncol 2006,24(1): 129.
91. Stewart, D.J., Arnold, A., Dent, S.F. et al. Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer. Lung 2005, 183(4): 265.
92. Iwamoto, M., Wagner, J.A., Gottesdiener, K.M. et al. A Phase I study evaluating the safety, tolerability, and pharmacokinetics of oral vorinostat (VOR) in patients with advanced cancer. Proc Am Assoc Cancer Res 2006, 47: Abst 2907.
93. Barragan, P.E.J., Hernandez, A.J.C. Efficacy of atomoxetine treatment in children with ADHD and epilepsy. Epilepsia 2005, 46(Suppl 6): Abst p718.
94. Whitaker, J., Weeks, P., Stark, S. et al. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A - Initial experiences. Eur J Neurol 2005, 12(12): 947.
95. Miller, A. et al. Treatment of pseudobulbar affect in patients with multiple sclerosis: A double-blind, placebo-controlled, multicenter study assessing the safety and efficacy of AVP-923 (dextromethorphan/quinidine). J Neurol Sci 2005, 238(Suppl 1): Abst 0546.
96. Husain, A. et al. Weight loss in narcolepsy with sodium oxybate. Sleep 2005, 28(Abst Suppl): Abst 0639.
97. Feldman, N. Sodium oxybate, alone and in combination with modafinil, is safe and well-tolerated for the treatment of narcolepsy. Sleep 2005, 28(Abst Suppl): Abst 0638.
98. Duntley, S., Wells, R., Svoboda, J., Powell, E., Reploeg, M. The arousal threshold and neurocognitive effects of sodium oxybate. Sleep 2005, 28(Abst Suppl): Abst 0147.
99. Siemers, E.R., Quinn, J.F., Kaye, J. et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 2006, 66(4): 602.
100. Spiegel, K., Huang, S., Barrett, J. Add-on treatment for partial seizures of pregabalin in not affected by the concomitant use of an oral contraceptive or by menopausal status. Epilepsia 2005, 46(Suppl 6): Abst p243.
101. Reimherr, F.W. et al. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry 2005, 58(2): 125.
102. Mohs, R., Rotz, B., Xu, J. et al. Duloxetine vs. placebo in the treatment of elderly patients with MDD. Eur Neuropsychopharmacol 2005, 15(Suppl 3): Abst P.2.106.
103. Minzenberg, M.J. et al. Blunted hormone responses to ipsapirone are associated with trait impulsivity in personality disorder patients. Neuropsychopharmacology 2006, 31(1): 197.
104. Gleicher, N., Barad, D.H. Dehydroepiandrosterone (DHEA) pre-treatment and ovulation induction for in vitro fertilization among women with a history of decreased ovarian reserve. Fertil Steril 2005, 84(Suppl 1): Abst O-101.
105. Cron, R.Q., Cherian, S., Kreiger, P.A., Behrens, E.M. The use of anakinra in the treatment of cytophagic histiocytic panniculitis. Arthritis Rheum 2005, 52(9, Suppl): Abst F85.
106. Katsambas, A., Stratigos, A.J., Dessinioti, C., Antoniou, C. A modified regimen combining a two-compound product calcipotriol/betamethasone dipropionate with narrow-band (nB) UVB phototherapy in patients with severe psoriasis vulgaris. J Eur Acad Dermatol Venereol 2005, 19(Suppl 2): Abst P06.42.
107. Braathen, L.R., Yawalkar, N. Successful treatment of severe recalcitrant palmoplantar pustular psoriasis with combination of efalizumab and acitretin. J Eur Acad Dermatol Venereol 2005, 19(Suppl 2): Abst P06.104.
108. Knolle, J., Dong, L., Kreuz, W., Frank, J., Bork, K., Rosenkranz, B. Use of icatibant, a bradykinin B2 receptor antagonist in treatment of hereditary angioedema attacks. Allergy Clin Immunol Int 2005(Suppl 1): Abst 1587.
109. Rasmussen, G.L. et al. Etoricoxib provides analgesic efficacy to patients after knee or hip replacement surgery: A randomized, double-blind, placebo-controlled study. Anesth Analg 2005, 101(4): 1104.
110. Brambilla, R., Grinyo, J., Shoker, A. et al. Preliminary results of a 12-month study with enteric-coated mycophenolate sodium (EC-MPS), basiliximab, and NEORAL C-2 comparing two investigational steroid regimens (without steroids or short-term use of steroids) with standard steroid treatment in de nova kidney recipients. Nephrology 2005, 10(Suppl): Abst T-PO50027.
111. Halkin, A. et al. Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: Results from the TAXUS-IV Trial. Am Heart J 2005, 150(6): 1163.
112. Tan, H.P., Kaczorowski, D., Basu, A. et al. Steroid-free tacrolimus monotherapy after pretransplantation thymoglobutin or Campath and laparoscopy in living donor renal transplantation. Transplant Proc 2005, 37(10): 4235.
113. Jain, A., Orloff, M., Kashyap, R. et al. Does valganciclovir hydrochloride (Valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Transplant Proc 2005, 37(7): 3182.
114. Gilbert, D.L., Ridel, K.R., Sallee, F.R., Zhang, J., Lipps, T.D., Wassermann, E.M. Comparison of the inhibitory and excitatory effects of ADHD medications methylphenidate and atomoxetine on motor cortex. Neuropsychopharmacology 2006, 31(2): 442.
115. Ma, J.D., Nafziger, A.N., Rhodes, G., Liu, S., Gartung, A.M., Bertino, J.S., Jr. The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe. J Clin Pharmacol 2006, 46(1): 103.
116. Hasler, C. et al. Sustained 24-hour blockade of the renin-angiotensin system: A high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther 2005,78(5): 501.
117. Degen, L. et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005, 129(5): 1430.